In short
This article discusses the ongoing clinical trial investigating the use of RBL007.2, a component of the cancer vaccine BNT116, in combination with cemiplimab for the treatment of advanced non-small cell lung cancer (NSCLC). The study aims to evaluate the effectiveness and safety of this combination therapy compared to cemiplimab alone in patients with tumors expressing high levels of PD-L1.
At a glance
- Study Type
- Phase 2 clinical trial
- Main Treatment
- BNT116 (containing RBL007.2) + Cemiplimab
- Comparison Treatment
- Cemiplimab alone
- Target Condition
- Advanced Non-Small Cell Lung Cancer (NSCLC)
- Key Eligibility
- PD-L1 expression ≥50%, no prior systemic treatment for recurrent/metastatic NSCLC
- Primary Endpoint
- Objective Response Rate (ORR) assessed by blinded independent review
- Treatment Duration
- Up to 108 weeks
- Follow-up Period
- Up to 7 months
What is RBL007.2?
RBL007.2 is a component of an experimental cancer vaccine called BNT116, which is being developed to treat advanced non-small cell lung cancer (NSCLC). This vaccine is part of a class of treatments known as FixVac, which uses genetic material (RNA) to stimulate the immune system to fight cancer cells.
BNT116 contains several active substances, including RBL007.2, which are all forms of nucleic acids. These substances work together to potentially enhance the body's immune response against lung cancer cells.
How is RBL007.2 Being Studied?
RBL007.2, as part of BNT116, is currently being investigated in a Phase 2 clinical trial called EMPOWERVAX Lung 1. This study is comparing the effectiveness and safety of BNT116 in combination with another drug called cemiplimab (an anti-PD-1 antibody) against cemiplimab alone in patients with advanced NSCLC.
The study focuses on patients whose tumors express high levels of a protein called PD-L1, which is found in 50% or more of their tumor cells. PD-L1 is a molecule that cancer cells sometimes use to evade the immune system.
Who Can Participate in the Study?
The study has specific criteria for who can participate. Some key inclusion criteria are:
- Patients with advanced NSCLC (stage IIIB, IIIC, or IV) who haven't received prior systemic treatment for their cancer
- Tumors must express PD-L1 in 50% or more of cells
- Patients must have at least one measurable tumor
- Patients must be in relatively good overall health (ECOG performance status ≤1)
Some key exclusion criteria include:
- Never-smokers (defined as smoking ≤100 cigarettes in a lifetime)
- Patients with certain gene mutations (EGFR, ALK, ROS1)
- Patients with untreated brain metastases
- Patients with a history of certain autoimmune diseases or interstitial lung disease
What Are the Study Goals?
The main goal of the study is to assess how well the combination of BNT116 (containing RBL007.2) and cemiplimab works compared to cemiplimab alone. This is primarily measured by the objective response rate (ORR), which refers to the proportion of patients whose tumors shrink or disappear after treatment.
Other important goals include:
- Measuring how long the treatment effects last (duration of response)
- Assessing how long patients live without their cancer getting worse (progression-free survival)
- Evaluating overall survival
- Monitoring the safety of the treatments by tracking side effects
How is the Study Designed?
The study is divided into three main periods:
- Screening Period: Up to 28 days where patients are evaluated to see if they qualify for the study.
- Treatment Period: Lasting up to 108 weeks (about 2 years). Patients are randomly assigned to one of two groups:
- Arm A: Patients receive only cemiplimab through an intravenous (IV) infusion.
- Arm B: Patients receive both BNT116 (which includes RBL007.2) through an IV injection and cemiplimab through an IV infusion.
- Follow-up Period: Lasting up to 7 months after the treatment period ends.
Potential Benefits and Risks
While the potential benefits of RBL007.2 as part of BNT116 are still being studied, it's hoped that this treatment could improve outcomes for patients with advanced NSCLC. However, as with all experimental treatments, there may be risks and side effects that are not yet fully known.
The study is carefully monitoring for any side effects or safety concerns. Patients considering participating in this or any clinical trial should discuss the potential risks and benefits thoroughly with their healthcare provider.